Focal brain inflammation and autism
- 19k Downloads
Increasing evidence indicates that brain inflammation is involved in the pathogenesis of neuropsychiatric diseases. Autism spectrum disorders (ASD) are characterized by social and learning disabilities that affect as many as 1/80 children in the USA. There is still no definitive pathogenesis or reliable biomarkers for ASD, thus significantly curtailing the development of effective therapies. Many children with ASD regress at about age 3 years, often after a specific event such as reaction to vaccination, infection, stress or trauma implying some epigenetic triggers, and may constitute a distinct phenotype. ASD children respond disproportionally to stress and are also affected by food and skin allergies. Corticotropin-releasing hormone (CRH) is secreted under stress and together with neurotensin (NT) stimulates mast cells and microglia resulting in focal brain inflammation and neurotoxicity. NT is significantly increased in serum of ASD children along with mitochondrial DNA (mtDNA). NT stimulates mast cell secretion of mtDNA that is misconstrued as an innate pathogen triggering an auto-inflammatory response. The phosphatase and tensin homolog (PTEN) gene mutation, associated with the higher risk of ASD, which leads to hyper-active mammalian target of rapamycin (mTOR) signalling that is crucial for cellular homeostasis. CRH, NT and environmental triggers could hyperstimulate the already activated mTOR, as well as stimulate mast cell and microglia activation and proliferation. The natural flavonoid luteolin inhibits mTOR, mast cells and microglia and could have a significant benefit in ASD.
autism spectrum disorders
brain-derived neurotrophic factor
monocyte chemotactic protein
mammalian target of rapamycin
phosphatase and tensin homolog
selective serotonin re-uptake inhibitor
tumor necrosis factor
tuberous sclerosis protein 1 and 2
vascular endothelial growth factor.
Focal brain inflammation
Increasing evidence indicates that brain inflammation is important in the pathogenesis of neuropsychiatric disorders [1, 2]. Autism spectrum disorders (ASD) are pervasive neuro-developmental disorders characterized by varying degrees of deficiencies in social interactions, intelligence, and language, as well as the presence of stereotypic behaviors [3, 4, 5, 6]. Recent results from the Centers of Disease Control in the USA indicate that as many as 1/80 children have ASD . Many such children regress at about age 3 years, often after a specific event such as reaction to vaccination, infection [8, 9], trauma [10, 11], toxic exposures  or stress , implying the importance of some environmental triggers [14, 15].
Increasing evidence points to some immune dysfunction/inflammation in ASD [16, 17]. The markers of inflammation identified in the brain and cerebrospinal fluid (CSF) of many ASD patients include TNF, IL-6 and monocyte chemotactic protein 1 (MCP-1), the latter of which also is chemotactic for mast cells . Pro-inflammatory cytokine mRNA (IL-1α, IL-1β, IL-6 and TNF-α) is increased in brain inflammation and has been associated with hippocampal and cerebral damage . Mast cells are a rich source of IL-6 and TNF . In fact, mast cells are the only immune cells that store pre-formed TNF and can release it rapidly upon stimulation .
Mast cells and cytokines such as IL-6 and TNF are also implicated in disruption of the blood–brain barrier (BBB) [21, 22, 23], which may be malfunctioning or leaky in ASD as evidenced by the presence of circulating auto-antibodies directed against the fetal brain proteins [24, 25, 26, 27]. We had reported that the cytokine IL-33 synergizes with inflammatory neuropeptides to stimulate mast cells and result in increased vascular permeability . IL-33 has been considered an alarmin, acting through mast cells to alert the innate immune system [29, 30], and has recently been linked to brain inflammation [31, 32, 33].
We have also reported that neurotensin (NT) and corticotropin-releasing hormone (CRH), secreted under stress, synergistically stimulate mast cells, leading to increase vascular permeability  and contribute to BBB disruption . We further showed that NT stimulates mast cell secretion of vascular endothelial growth factor (VEGF) , which is also vasodilatory. NT also increases expression of CRH receptor-1 (CRHR-1) , activation of which by CRH increases allergic stimulation of human mast cells .
NT is a vasoactive peptide originally isolated from the brain , but also found in the gut where it has been implicated in inflammation , and in increased intestinal permeability in rodents . NT is also increased in the skin following acute stress, stimulates skin mast cells and increases vascular permeability in rodents . NT stimulates rodent peritoneal mast cells to secrete histamine and elevates histamine plasma levels through activation of specific NT receptors (NTR) [43, 44, 45]. Moreover, NT is rapidly degraded by mast cell proteases [34, 46] implying tight regulation of its activity.
Mast cells are hemopoietic-derived tissue immune cells responsible for allergies, but also implicated in immunity  and inflammation . Mast cells can produce both pro- and anti-inflammatory mediators  and may have immuno-modulatory functions [47, 49, 50, 51]. It is, therefore, of interest that allergic-like reactions are common in ASD children [52, 53] implying activation of mast cells by non-allergic triggers . The richest source of mast cells in the brain is the diencephalon  that regulates behavior, while the highest concentration of NTR is in the Broca area , which regulates language, known to be lost in many children with ASD. Mast cells are responsible for eliciting neutrophil infiltration that promotes inflammation . Mast cell-microglial interactions are important in neuroinflammatory diseases [57, 58]. Microglia are the innate brain immune cells that are increasingly implicated in a number of neuropsychiatric diseases . In fact, abnormal microglial growth and activation was recently reported in the brain of ASD patients [60, 61]. Microglia express NTR3, activation of which leads to their proliferation .
Neurotensin actions relevant to autism spectrum disorder (ASD) pathogenesis
Activation and proliferation of microglia
Activation of mast cells
Blood–brain-barrier disruption and inflammation
Disruption of gut-blood barrier
Leaky gut and inflammation
Mast cell stimulation, especially in the subgroup of ASD patients with allergic symptoms
Augmentation of allergic symptoms
Extracellular secretion of mitochondrial components that act as innate pathogens
Stimulation of glutamate receptors
Key pathologic processes in ASD*
Anti-brain protein auto-antibodies
Brain and gut inflammatory markers
High anxiety and response to stress
Epigenetic activation of ASD susceptibility genes
In spite of the fact that almost 100 gene mutations have been identified in patients with ASD [77, 78], they do not explain more than a few percent of ASD cases . High risk for developing ASD has been associated with mutations leading to decreased phosphatase and tensin homolog (PTEN) and tuberous sclerosis protein 1 and 2 (TSC1/2) . These proteins are upstream inhibitors of the mammalian target of rapamycin (mTOR) [77, 79], which leads to microglia and mast cell proliferation [80, 81]. Activation of susceptibility genes is being increasingly invoked to explain ASD [7, 82]. A recent paper reported that offspring of maternal immune activation in mice led to increased IL-6 and IL-17, and contributed to ASD-related behaviors ; repopulation of control irradiated mice with bone marrow derived from affected mothers did not induce those effects suggesting the contribution of some epigenetic environmental influences. Stimulation of mTOR in subjects with overactive mTOR due to gene mutations, leading to low PTEN, would contribute to a form of epigenetic signal.
Behavioral interventions are the most common treatment approaches , but do not address the core ASD symptoms [84, 85]. Psychotropic drugs are used much too often in ASD [86, 87, 88]. Such drugs include antipsychotic medications , the newer atypical compounds [90, 91] risperidone [92, 93] and aripiprazole  for obsessive-compulsive symptoms, aggression and self-injury, as well as methylphenidate for hyperactivity . However, two recent reviews concluded that there is insufficient evidence to support any benefit of psychotropic drugs  or selective serotonin re-uptake inhibitor (SSRIs)  in ASD. In fact, the SSRI citalopram may actually be detrimental , especially in children . Moreover, a recent paper reported that citalopram administration perinataly altered cortical network function and led to ASD-like behaviors in rodents .
The prevalence of ASD continues to rise, but there is no clinically effective drug for the core ASD symptoms. Unfortunately, the lack of distinct pathogenesis and biomarkers makes it difficult to develop effective treatments. Stimulation of mTOR, which is already activated due to PTEN mutations, by NT, CRH and/or IL-33, could serve as novel targets for drug development. NTR and CRHR-1 antagonists could, therefore, be used in ASD, along with luteolin.
Aspects of the work discussed were funded in part by the Autism Research Institute, the National Autism Association, Safe Minds, and Theta Biomedical Consulting and Development Co. Inc. (Brookline, MA).
- 15.Goines PE, Ashwood P: Cytokine dysregulation in autism spectrum disorders (ASD): Possible role of the environment. Neurotoxicol Teratol 2012.Google Scholar
- 17.Theoharides TC, Angelidou A, Alysandratos KD, Zhang B, Asadi S, Francis K, Toniato E, Kalogeromitros D: Mast cell activation and autism. Biochim Biophys Acta 1822, 2012:34–41.Google Scholar
- 18.Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng Z, Miniati A, Kalogeromitros D: Mast cells and inflammation. Biochim Biophys Acta 1822, 2010:21–33.Google Scholar
- 20.Zhang B, Weng Z, Sismanopoulos N, Asadi S, Therianou A, Alysandratos KD, Angelidou A, Shirihai O, Theoharides TC: Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells. Int Arch Allergy Immunol 2012,159(1):23–32.PubMedPubMedCentralCrossRefGoogle Scholar
- 28.Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, Peterson E, Leeman S, Conti P: IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 2010, 107:4448–4453.PubMedPubMedCentralCrossRefGoogle Scholar
- 32.Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, Girard JP: Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012, 188:3488–3495.PubMedCrossRefGoogle Scholar
- 36.Vasiadi M, Therianou A, Alysandratos KD, Katsarou-Katsari A, Petrakopoulou T, Theoharides A, Papadavid E, Stavrianeas N, Antoniou C, Kalogeromitros D, Theoharides TC: Serum neurotensin (NT) is increased in psoriasis and NT induces VEGF release from human mast cells. Br J Dermatol 2012, 166:1349–1352.PubMedPubMedCentralCrossRefGoogle Scholar
- 56.Walker ME, Hatfield JK, Brown MA: New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action? Biochim Biophys Acta 1822, 2012:57–65.Google Scholar
- 72.Zhang B, Alysandratos KD, Angelidou A, Asadi S, Sismanopoulos N, Delivanis DA, Weng Z, Miniati A, Vasiadi M, Katsarou-Katsari A, Miao B, Leeman SE, Kalogeromitros D, Theoharides TC: Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol 2011, 127:1522–1531.PubMedPubMedCentralCrossRefGoogle Scholar
- 92.McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314–321.PubMedCrossRefGoogle Scholar
- 97.Williams K, Wheeler DM, Silove N, Hazell P: Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010, 8:CD004677.Google Scholar
- 98.King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L: Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009, 66:583–590.PubMedPubMedCentralCrossRefGoogle Scholar
- 110.Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y, Moehle C, Fuchshofer R, Langmann T: Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J Neuroinflammation 2010, 7:3.PubMedPubMedCentralCrossRefGoogle Scholar
- 113.Kempuraj D, Tagen M, Iliopoulou BP, Clemons A, Vasiadi M, Boucher W, House M, Wolferg A, Theoharides TC: Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol 2008, 155:1076–1084.PubMedPubMedCentralCrossRefGoogle Scholar
- 115.Franco JL, Posser T, Missau F, Pizzolatti MG, Dos Santos AR, Souza DO, Aschner M, Rocha JB, Dafre AL, Farina M: Structure-activity relationship of flavonoids derived from medicinal plants in preventing methylmercury-induced mitochondrial dysfunction. Environ Toxicol Pharmacol 2010, 30:272–278.PubMedPubMedCentralCrossRefGoogle Scholar
- 118.Sadakata T, Shinoda Y, Oka M, Sekine Y, Sato Y, Saruta C, Miwa H, Tanaka M, Itohara S, Furuichi T: Reduced axonal localization of a Caps2 splice variant impairs axonal release of BDNF and causes autistic-like behavior in mice. Proc Natl Acad Sci USA 2012,109(51):21104–21109.PubMedPubMedCentralCrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.